Pediatric Radiology

, Volume 47, Issue 12, pp 1659–1669 | Cite as

Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis

  • Yoshiko Matsubara
  • Osamu Miyazaki
  • Motomichi Kosuga
  • Torayuki Okuyama
  • Shunsuke Nosaka
Original Article
  • 220 Downloads

Abstract

Background

Although enzyme replacement therapy (ERT) is an effective treatment for mucopolysaccharidosis (MPS) types I, II, IVA and VI, its effectiveness in children with central nervous system (CNS) disorders is said to be poor because the blood–brain barrier cannot be penetrated by ERT drugs.

Objective

To assess CNS involvement in mucopolysaccharidosis at the start of enzyme replacement therapy and to investigate the time course of ERT in the central nervous system.

Materials and methods

We performed brain MRI in 17 children and young adults who underwent ERT. The clinical severity was classified as attenuated or severe by a specialist pediatrician, based on the clinical symptoms and genotypes. At the start of ERT, we scored nine parameters using two- or three-point scales based on the severity of the disease revealed on MRI scans. After the start of ERT, we compared the initial and follow-up MRI scans, and classified the findings as no change, improved or worse. We then compared the results with the changes in clinical findings.

Results

At the start of ERT, comparison of the clinical symptoms and image scores revealed differences between severe and attenuated mucopolysaccharidosis. The scores in patients with severe MPS ranged from 9 to 16 (mean 12.2); for patients with attenuated MPS, they ranged from 2 to 11 (mean 6.4). Images of the four patients with severe MPS showed ventricular dilation and brain atrophy. Such findings were made in only 2 of 13 patients with attenuated MPS. The results after the start of ERT showed that 11/17 (65%) patients manifested improvement or no change. All five patients with MPS I experienced improvement in some regions. There were no new lesions. One patient with MPS II experienced worsening of his CNS symptoms, and his MRI findings revealed more severe ventricular dilation, brain atrophy and white matter lesions.

Conclusion

Ventricular dilation and brain atrophy on imaging studies might represent useful markers in predicting the severity of mucopolysaccharidosis and worsening of CNS symptoms. Enzyme replacement therapy improves CNS images in MPS I and has an inhibitory effect on the occurrence of new lesions in MPS II.

Keywords

Brain Children Enzyme replacement therapy Magnetic resonance imaging Mucopolysaccharidosis Phenotype Young adults 

Notes

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39:215–224CrossRefPubMedGoogle Scholar
  2. 2.
    Spranger JW (2016) Mucopolysaccharidoses. In: Kliegman RM (ed) Nelson textbook of pediatrics, 20th edn. Elsevier, Philadelphia, pp 737–743Google Scholar
  3. 3.
    Neufeld EF, Muenzer J (2000) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452Google Scholar
  4. 4.
    Muenzer J (2004) The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 144:27–34CrossRefGoogle Scholar
  5. 5.
    Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 12:377–386CrossRefGoogle Scholar
  6. 6.
    Miebach E (2005) Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr Suppl 94:58–60CrossRefPubMedGoogle Scholar
  7. 7.
    Liang J, Singhal A (2016) Regression of ventriculomegaly following medical management of a patient with Hurler syndrome. J Neurosurg Pediatr 17:537–539CrossRefPubMedGoogle Scholar
  8. 8.
    Wang RY, Cambray-Forker EJ et al (2009) Treatment reduces or stabilizes brain imaging abnormalities in patients with mucopolysaccharidosis I and II. Mol Genet Metab 98:406–411CrossRefPubMedGoogle Scholar
  9. 9.
    Lee C, Dineen TE, Brack M et al (1993) The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol 14:1285–1292PubMedGoogle Scholar
  10. 10.
    Manara R, Priante E, Grimaldi M et al (2011) Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. J Inherit Metab 34:763–780CrossRefGoogle Scholar
  11. 11.
    Valayannopoulos V, Boddaert N, Barbier V et al (2010) Cognitive and neuroradiological improvement in three patients with attenuated mucopolysaccharidosis I treated by laronidase. Mol Genet Metab 100:20–23CrossRefPubMedGoogle Scholar
  12. 12.
    Matheus MG, Castillo M, Smith JK et al (2004) Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 46:666–672CrossRefPubMedGoogle Scholar
  13. 13.
    Parini R, Rigoldi M, Tedesco L et al (2015) Enzymatic replacement therapy for Hunter disease: up to 9 years experience with 17 patients. Mol Genet Metab Rep 3:65–74CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zafeiriou DI, Batzios SP (2013) Brain and spinal MR imaging findings in mucopolysaccharidoses: a review. AJNR Am J Neuroradiol 34:5–13CrossRefPubMedGoogle Scholar
  15. 15.
    Seto T, Kono K, Morimoto K et al (2001) Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 50:79–92CrossRefPubMedGoogle Scholar
  16. 16.
    Kara S, Sherr EH, Barkovich AJ (2008) Dilated perivascular spaces: an informative radiologic finding in Sanfilippo syndrome type A. Pediatr Neurol 38:363–366CrossRefPubMedGoogle Scholar
  17. 17.
    Taccone A, Tortori Donati P, Marzoli A et al (1993) Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings. Pediatr Radiol 23:349–352CrossRefPubMedGoogle Scholar
  18. 18.
    Murata R, Nakajima S, Tanaka A et al (1989) MR imaging of the brain in patients with mucopolysaccharidosis. AJNR Am J Neuroradiol 10:1165–1170PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Division of Radiology, National Center for Child Health and DevelopmentTokyoJapan
  2. 2.Department of Diagnostic RadiologyHiroshima UniversityHiroshimaJapan
  3. 3.Division of Medical Genetics, National Center for Child Health and DevelopmentTokyoJapan
  4. 4.Department of Clinical Laboratory Medicine, National Center for Child Health and DevelopmentTokyoJapan

Personalised recommendations